The high frequency of relapse of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to identify targeted therapies that can improve patient outcomes. The dynamic relationship between cyclin E and PKCiota frequent overexpression in high-grade ovarian tumors poses a novel pathway for therapeutic investigation. We hypothesized that a phosphoinositide 3-kinase (PI3K)-dependent signaling pathway activating PKCiota perpetuates cyclin E deregulation during ovarian tumorigenesis. We observed a positive correlation between PKCiota and cyclin E in a panel of 19 ovarian cancer cell lines. Modulation of cyclin E had no effect on PKCiota knockdown/overexpression; however, PKCiota differentially regulated cyclin E expression. In the serous ovarian cancer cells (IGROV and OVCAR-3), shPKCiota decreased proliferation, caused a G1 arrest and significantly prolonged overall survival in xenograft mouse models. In vitro, shPKCiota decreased the ability of IGROV cells to grow under anchorage-independent conditions and form aberrant acini, which was dependent on Ad-cyclin E or Ad-LMW-E expression. Reverse-phase protein array analysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the association between phospho-PKCiota levels and PI3K pathway activation. Inhibitors of PI3K coordinately decreased phospho-PKCiota and cyclin E protein levels. In conclusion, we have identified a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis.
INTRODUCTION
High-grade serous ovarian cancer accounts for over 70% of ovarian cancer cases with a 5-year survival rate of~15%, making high-grade serous ovarian cancer a highly aggressive and deadly form of ovarian cancer. 1 The emergence and affordability of nextgeneration sequencing in the clinic has slowly demystified the molecular origins of ovarian cancer progression highlighting defects within key homologous recombination genes (for example, BRCA1, BRCA2, and PALB2) giving rise to ovarian cancer. 2 Aside from defects within homologous recombination DNA repair genes and tumor suppressors (for example, phosphatase and tensin homolog and TP53), cyclin E amplification/ overexpression is the most frequently associated genetic alteration observed in ovarian tumors (14%-21%) that correlates with decreased overall and progression-free survival in ovarian cancer patients. 3 However, a complete understanding of the molecular initiators of cyclin E expression in ovarian tumorigenesis is severely lacking and requires further investigation. Cyclin E overexpression correlated with poor overall survival in several tumor types including breast, ovarian, lung and pancreatic cancer. 3, 4 The low-molecular-weight isoforms of cyclin E (LMW-E) specifically correlate with advanced stages and grade of ovarian cancer. 5, 6 In addition, tumors that typically overexpress LMW-E exhibit higher CDK2 activity and poor overall survival in ovarian tumors compared with full-length expression of cyclin E alone, highlighting the need to understand the mechanism of cyclin E deregulation in ovarian cancer. 5, 7 PKCiota has emerged as a bonafide oncogene in several types of cancers, including ovarian cancer. 8 In addition to being genomically amplified in ovarian cancer as part of the 3q26.2 amplicon, PKCiota is induced by several potent oncogenic regulators (for example, phosphoinositide 3-kinase (PI3K), Kras, epidermal growth factor receptor, AKT and mammalian target of rapamycin) and is thus differentially expressed between ovarian cancer and normal epithelial ovarian tissue, 9 and represents the only protein kinase C (PKC) isoform that has been designated as an oncogene in ovarian cancer. 8 . PKCiota induction signals oncogenic transformation in lung, pancreatic and ovarian tumor types. 10, 11 The oncogenic transformation of lung squamous cell carcinoma is highly dependent on co-induction of PKCiota and SOX2, signaling the transformative potential of PKCiota. 12 In ovarian tumors, the expression of PKCiota exhibits a significant correlation with a reduced median survival time as well as increased expression of cyclin E. 9 Cyclin E deregulation correlates with decreased survival in several tumor types, suggesting that in ovarian cancer PKCiota has a pivotal role in the deregulation of cyclin E as a molecular driver of ovarian cancer progression.
Therefore, we hypothesized that cyclin E is a downstream oncogenic target of PKCiota, and that activation of PKCiota by phosphatidylinositol 3-kinase signal would further activate the signaling between PKCiota and cyclin E. In addition, we posit that attenuation of the PI3K/PKCiota/cyclin E pathway is an actionable target in ovarian cancer. We show that depletion of PKCiota expression in high-grade serous ovarian cancer cell lines inhibits proliferation, alters the cell cycle profile, inhibits acini filling in vitro and prolongs survival in xenograft mouse models. Inhibition of the PI3K pathway attenuates the induction of cyclin E by PKCiota, signaling an actionable target for clinical advancement.
RESULTS

Cyclin E and PKCiota exhibit in vivo and in vitro correlations
We previously established a positive correlation between PKCiota expression and cyclin E deregulation in tumor samples derived from serous ovarian cancer patients that dictates decreased survival and an overall poor prognosis. 13 To determine whether ovarian cancer cell lines show a similar coordinate expression of PKCiota and cyclin E, we examined a panel of 19 ovarian cancer cell lines for PKCiota, phospho-PKCiota and cyclin E expression ( Figure 1a ). Phospho-PKCiota was used as the functional, activated form of PKCiota protein and the cutoff of 1.0 (from densitometry values) to separate the cells into high and low phospho-PKCiota-expressing cells. The FUOV 1, OVCAR3, IGROV and OAW 42 cell lines exhibited the highest levels of phospho-PKCiota and total cyclin E (full-length and LMW-E), whereas 59M and OVCA 420 had low expression of both PKCiota and cyclin E. The remainder of cell lines had an intermediate amount of both PKCiota and cyclin E expression. The phospho-PKCiota levels were dichotomized into high and low phospho-PKCiota groups and cyclin E levels were quantitated by densitometric analysis. A positive and significant correlation (P = 2.5 × 10 − 5 ; r = 0.793) was established for the relationship between phospho-PKCiota and cyclin E (Figures 1b and c) in the 19 cell lines. To determine whether this positive relationship between cyclin E and phospho-PKCiota persists in tissue samples of patients with ovarian cancer, we examined the expression of these proteins in nine tumor tissue samples (Figure 1d ). PKCiota and cyclin E levels exhibited similar expression patterns to the cell lines with either high PKCiota/high cyclin E (lanes 1, 2 and 5) or low PKCiota/low cyclin E (lanes 3 and 6-9). The consistency between cyclin E and PKCi expression in both ovarian cancer cell lines and patient samples provided an opportunity to examine the cause and effect relationship between these two proteins in transformation and oncogenesis.
Cyclin E overexpression does not alter PKCiota expression
Although the correlation has been established between PKCiota and cyclin E, the functional significance and mechanism of the apparent codependency is not known. The oncogenic transformative properties of cyclin E have been well documented in ovarian cancer; 5,14 therefore, we initially investigated whether overexpression of either full-length or LMW-E leads to modulation of PCKiota levels or activity. To test this hypothesis, IGROV and OVCA420 cells were chosen for further analysis, as they represent opposing sides of the cyclin E expression profile of the serous epithelial ovarian cancer subtype ( Figure 1a ). IGROV cells express high levels of PKCiota and cyclin E, whereas OVCA420 cells have relatively low endogenous levels of PKCiota and cyclin E. Both cell lines were infected with adenovirus containing full length (Adcyclin EL) or LMW-E forms of cyclin E (Ad-LMW-E), to further examine whether cyclin E could alter PKCiota levels (Supplementary Figure S1) .
Cyclin E was overexpressed at the expected molecular weights after both adenoviral-and pcDNA vector-mediated expression ( Supplementary Figures S1a and b ). However, after 48, 72 and 144 h of full-length cyclin E (EL) or LMW-E expression in IGROV cells, PKCiota levels and phosphorylation remained unaffected (Supplementary Figure S1a) . Similarly, infection or transfection of OVCA420 with EL or LMW-E did not alter the level or phosphorylation of endogenous PKCiota (Supplementary Figure   S1b ). Collectively, our results show that the expression of cyclin E or LMW-E does not affect PKCiota protein level or activity.
PKCiota expression regulates cyclin E Our analysis of cyclin E overexpression studies suggest that the positive correlation observed between these two proteins is likely to be a direct result of PKCiota regulation of cyclin E and not due to the cyclin E-mediated regulation of PKCiota. To test this hypothesis, cyclin E expression was examined in IGROV cells with stable knockdown of PKCiota via short hairpin RNA (shRNA; Figure 2a ). Two different PKCiota shRNAs were used (that is, construct 7 and 8), targeting two different exons of PKCiota (exons 13 and 14) , which resulted in the downregulation of PKCiota and decreased levels of phospho-PKCiota (active form of PKCiota), cyclin E, CDK4 and cyclin D1 (Figure 2a ). Overall, there was a statistically significant reduction in full-length cyclin E (cyclin EL) as well as LMW-E expression in the shPKCiota versus the shControl clones (P = 0.0021; Figure 2b and supplementary Figure S2a ). In addition, linear regression analysis revealed that decreased PKCiota expression was proportional to that of cyclin E protein expression (r = 0.803; P = 0.0005; Figure 2c ). To further support our hypothesis and to rule out clonal variation among the shControl and shPKCiota clones (Figure 2a ), PKCiota was overexpressed in its wild type (WT) or constitutively active (CA) form along with green fluorescent protein (GFP) in IGROV cells ( Figure 2d ). Following transfection, the cells were sorted for GFP+ cells. As expected, the GFP+ cells cotransfected with the WT or CA PKCiota constructs demonstrated overexpression of PKCiota and phospho-PKCiota ( Figure 2d ). Both PKCiota WT and CA cells also show increased expression of cyclin E (EL and LMW-E) and cyclin D1, CDK2 and p53 levels, and a decrease in expression of p27 protein. These studies suggest that PKCiota is an upstream mediator of cyclin E and several other G1 checkpoint proteins.
Depletion of PKCiota increases doubling time of cells
As loss of PKCiota alters the expression of several G1/S phase transition proteins (Figure 2d ), we examined the effect of PKCiotamediated cyclin E expression on proliferation, in IGROV shControl and shPKCiota-transfected cells (Supplementary Figure S2a) . Growth curve analysis showed that downregulation of PKCiota resulted in an increase in doubling time from 27.5 to 30.0 h (P = 0.043; Supplementary Figure S2b ). In addition, downregulation of PKCiota did not result in the induction of apoptosis (that is, no change in TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive or sub-G1 cells Supplementary Figure  S2c ). However, cell cycle analysis revealed that shPCKiota cells accumulated in the G1 phase with concomitant decrease in S phase ( Supplementary Figures S2d and e ). Such a cell cycle alteration is often suggestive of a more regulated cell cycle transition from G1 to S phase that could affect biological functions leading to transformation.
PKCiota expression alters acini formation in ovarian cancer cells As PKCiota is mislocalized or overexpressed in serous epithelial cancer, 13 its co-overexpression with cyclin E could lead to deregulation of acinar development, one of the hallmarks of oncogenicity. To test this hypothesis, ovarian cancer cells with either low (HeyA8 and 59M) or high (OVCAR3 and IGROV) PKCiota and cyclin E levels as determined by western blotting (Figure 3a , two-dimensional cultures) were subjected to culture on matrigel. The HeyA8 cells did not form acini and the 59M cells formed very small acini ( Figure 3b ). However, the OVCAR3 and IGROV cells formed acini that were significantly larger (Po 0.001; Figure 3c ) and of asymmetric size (P o 0.005; Figure 3d ) compared with those formed by the 59M cells. Western blot analysis using cell lysates prepared from two-dimensional cultured cells and three-dimensional (3D) acini showed that the levels of both cyclin E and PKCiota did not change significantly from two-dimensional cultures compared with 3D acini in OVCAR3 and IGROV cells ( Figure 3a ), suggesting that both proteins are likely to be important for the larger and asymmetrical acini formation. To interrogate whether the increased acini size could be attributed to the increased PKCiota in these cell lines, PKCiota gene expression was silenced in the IGROV cell line with shRNA and subjected to 3D cultures ( Figure 4 ). Two different IGROV shPKCiota-expressing cells were generated (using two different shRNA constructs against PKCiota) and both exhibited stable knockdown of PKCiota with a concomitant decrease in full-length and LMW cyclin E, Ovarian Tumor Tissue Samples (Table) . Relative levels of full-length cyclin E (also determined by densitometric analysis of western blottings) was next used to plot the mean phospho-PKCiota and cyclin EL levels increased as the lumen cleared ( Figure 4f ). In the shControl cells, the lumen was mostly undetectable and there was minimal expression of both E-cadherin (western blot analysis and confocal microscopy) and Alpha 6 integrin. Thus, our data suggest that polarity of acini forming cells is inhibited by PKCiota expression and on its downregulation the polarity is restored.
PKCiota facilitates anchorage-independent growth and tumor formation through cyclin E Next we examined the role of both PKCiota and cyclin E in anchorage-independent growth in a soft agar assay using the IGROV panel of shPKCiota and shControl cells ( Figure 4a ). All four cell lines were subjected to soft agar colony formation over a Immediately following cell sorting, the GFP+ cells were lysed and subjected to western blot analysis using antibodies to phospho-PKCiota, PKCiota, cyclin E, cyclin D1, CDK2 and p53. Actin was used as a loading control.
14-day period at which point colonies were enumerated. Results revealed that downregulation of PKCiota resulted in a significant decrease in the number of soft agar colonies formed as compared with shControl cells (Figure 5a ). As the downregulation of PKCiota also results in concomitant downregulation of total cyclin E (EL and LMW-E), we next asked whether cyclin E expression is necessary for growth advantage of IGROV cells in soft agar conferred by PKCiota. To this end, IGROV shPKCiota clones were infected with adenovirus harboring the cyclin E (EL and LMW-E) transgenes and were subjected to soft agar colony-formation assay. The results revealed that overexpression of cyclin E (EL and each of the LMW-E forms) increased the number of soft agar colonies in the shPKCiota clones to that of shControl clones (Figure 5b ). The reversion of the shPKCiota phenotype by reintroduction of cyclin E is statistically significant and consistent with cyclin E expression rescuing the cells from the inhibitory effects of shPKCiota on soft agar colony formation. Western blot analysis confirmed that cyclin E was expressed in these cells at the
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HeyA8 59M OVCAR3 IGROV Percent Asymmetric Acini Percent Asymmetric Acini ** * * p = 0.00006 ** p = 0.004 expected molecular weights, and that overexpression of any form of cyclin E did not alter the expression of PKCiota (Figure 5c ). Thus, decreasing cyclin E levels by depleting PKCiota is sufficient to decrease anchorage-independent growth of IGROV cells.
To examine whether PKCiota depletion alters tumor formation in mice, shControl and shPKCiota IGROV cells were introduced as xenografts into nude mice (Figures 5d and h) . By 45 days post inoculation, all 15 of the shControl mice were killed due to tumor burden; however, the survival of the shPKCiota mice was significantly increased (due to smaller tumors) to where 2 mice lived past 100 days (data not shown). This significantly increased survival (P = 0.0012) as shown in a Kaplan-Meier curve (Figure 5e ). The tumor volume of the shControl mice were significantly larger than the shPKCiota mice (Figure 5f ). The tumors formed in mice inoculated with the shPKCiota cells had reduced PKCiota, phosho-PKCiota, cyclin E and cleaved Parp compared with the tumors from the shControl mice (Figure 5d ). In addition, hematoxylin and eosin staining of the tumors revealed that when PCKiota was knocked down, the tumors had a lower grade and better differentiation characteristics compared with the shControl tumors ( Figure 5g ). Consistently, immunohistochemical staining of the shcontrol and shPKCiota tumors with PKCiota, cyclin E and Ki67 showed lower expression of all three proteins, suggesting that when PKCiota is downregulated it results with reduced proliferation (Figures 5g and h) . Therefore, downregulation of PKCiota resulting in cyclin E downregulation can prolong survival in mice bearing ovarian tumors.
PKCiota regulates cyclin E stability Cyclin D has been previously reported to be upregulated in response to PKCiota, through transcriptional activation of the cyclin D promoter. We next interrogated whether the regulation of cyclin E expression by PKCiota is also through transcriptional activation. We used two approaches to interrogate this hypothesis. First, a luciferase reporter assay was used with two different cyclin E reporter constructs, one with the WT cyclin E promoter (−207 to +79; termed pE) and one with a mutant cyclin E promoter harboring two mutations in the E2F binding sites (termed pME). These two constructs were used to test the luciferase activity in shControl compared with shPKCiota IGROV cells. Results revealed no difference in luciferase activity, between the shControl or shPKCiota cells for either promoter (data not shown). Next we quantitated cyclin E mRNA levels in IGROV cells transfected with PKCiota small interfering RNA (siRNA) post downregulation of PKCiota. Western blot analysis show that PKCiota, phospho-PKCiota and cyclin E are all downregulated at 24 h post siPKCiota transfection (Figure 6a ). However, quantitative reverse transcriptase-PCR analysis of cyclin E and PKCiota transcripts show that although the PKCiota transcript decreased within 24 h of PKCiota siRNA transfection, cyclin E mRNA levels remained unchanged at all time points examined (Figure 6b ). These results suggest that the regulation of cyclin E by PKCiota is most likely not via transcription.
Next we addressed whether PKCiota alters the transcriptional regulation of FBW-7, the ubiquitin ligase responsible for the degradation of cyclin. 15 To determine the effect of PKCiota knockdown on FBW7 expression, IGROV cells transiently silenced with siRNA against PKCiota were examined for changes in FBW7 expression, as a function of time, by quantitative reverse transcriptase-PCR analysis (Figure 6c ). The results revealed that in response to silencing of PKCiota, there was no change in the transcriptional regulation of FBW-7 at any of the time intervals (0-96 h) we examined. Thus, changes in FBW7 mRNA levels are likely not the cause of PKCiota knockdown-induced cyclin E degradation.
To determine whether changes in cyclin E protein levels are a result of proteosomal degradation following PKCiota downregulation, IGROV and 293T cells with PKCiota knocked down either stably or transiently, respectively, were treated with the proteasome inhibitor MG132 (Figures 6d and e ). Silencing PKCiota either stably in IGROV cells or transiently in 293T cells caused a decrease in cyclin E levels as seen in lane 3 (IGROV shPKCiota) and lane 7 (293T siPKCiota) compared with controls (lanes 1 and 5). However, on treatment of cells with MG132, cyclin E levels were markedly increased in both cell lines (Figures 6d and e ). Addition of MG132 to IGROV stable PKCiota knockdown cells (left panel) resulted in a modest accumulation of cyclin E as compared with 293T cells (right panel), which exhibited levels of cyclin E similar to siControl cells. Collectively, these results suggest that that the PKCiota-mediated downregulation of cyclin E occurs postranslationally.
PI3K regulates cyclin E through activation of PKCiota. Next we set out to identify other proteins in the PKCiota/cyclin E pathway that could be involved in the process of tumor progression. To this end, 293T cells transiently expressing WT, dominant-negative (DN) or CA PKCiota were subjected to an RPPA (reverse-phase protein array; Figure 7a ). As expected, cyclin E and PKCiota are increased in the WT and CA, but not DN or Mock (that is, GFP cells; Figure 7a ). Several proteins and pathways were identified as being differentially expressed between WT and CA compared with DN or control cells (Figure 7b ). Specifically, phosphorylation of AKT, GSK3, PDK1, TSC2, p70S6K, and mammalian target of rapamycin were increased, consistent with activation of the PI3K pathway, whereas phosphorylation of mitogen-activated protein kinase was increased consistent with activation of the RAS/mitogen-activated protein kinase pathway (Figure 7b , highlighted in red). Conversely, pathways leading to translation (decreased phosphoS6) and apoptosis (decreased caspase 9, highlighted in green) were inhibited, whereas anchorage-independent growth (increased cyclin E) and proliferation (increased c-myc, STAT3 and cyclin E) pathways are activated. These results suggest that MEK and PI3K pathways, which are known factors, that either influence or are influenced by PKCiota [16] [17] [18] [19] may also regulate cyclin E expression. We validated these findings in IGROV cell line with PKCiota stably silenced as compared with the shControl cells. Using the lysates of these cells, we were able to validate the RPPA data by western blot analysis (Supplementary Figure S3A ). As expected, cyclin E, Akt (S473 and T308), and phosphoS6 were decreased in response to PKCiota * p = 0.046 ** p = 0.030 *** p = 0.007 p = 0.0012 knockdown. However, in this cell line, GSK3 is minimally altered. Therefore, we hypothesized that inhibition of PI3K could also inhibit the phosphorylation of PKCiota, which could then downregulate cyclin E. To test this hypothesis, we treated IGROV parental ( Figure 7c ) cells and 293T cells (Supplementary Figure  S3B ) with increasing concentrations of two different PI3K inhibitors (GDC-0841 and PI-103) and examined the expression of PKCiota (total and phosphorylated forms). The levels of total PKCiota protein slightly decreased in IGROV-treated cells (Figure 7c ) and remained unchanged in 293T cells (Supplementary Figure S3B) . However, the levels of phospho-PKCi were reduced following treatment of cells with 5 μM GDC-0941 or 1.5 μM PI-103 (Figure 7c and Supplementary Figure  S3B ). Next, 293T cells were treated with aforementioned concentrations of each agent and levels of cyclin E and AKT (total and phospho-AKT) were monitored by western blot analysis (Supplementary Figure S3C) . Results revealed that not only was the active form of PKCiota (phospho-PKCiota) decreased in response to drug treatment but the levels of cyclin E (cyclin EL and LMW-E) and phospho-AKT were decreased as well.
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Next we interrogated whether PI3K can directly regulate cyclin E expression independent of PKCiota in ovarian cancer cell lines. To this end, we treated the IGROV shControl and IGROV shPKCiota cell lines with two different PI3K inhibitors, PI-103 and GDC-0941, and examined cyclin E and phospho-AKT expression (Figure 7d ). In the parental and shControl IGROV cell lines, PI3K inhibition resulted in a marked decrease in cyclin E expression. However, shPKCiota cell lines treated with PI3K inhibitors also resulted in a decrease in the levels of cyclin E. Collectively, these results suggest that PI3K or PKCiota inhibitors could provide a target for inhibition of several oncogenic pathways including cyclin E, PKCiota and PI3K, simultaneously in serous ovarian cancer tumors.
DISCUSSION
The role of cyclin E in ovarian cancer tumorigenesis has been extensively characterized but has provided few answers regarding the specific upstream activators that maintain a hierarchal role in influencing deregulation of the cell cycle via cyclin E. Thus, the observation that PKCiota expression correlates with cyclin E deregulation in ovarian cancer patient samples provides a plausible understanding of the tumorigensis pathway via a PKCiota → cyclin E activation pathway. In this study we have examined the relationship between PKCiota and cyclin E that highlights PI3K as an upstream mediator of PKCiota activation/ phosphorylation and have concluded that cyclin E has a significant role in the activation of ovarian cancer tumorigenesis via a PKCiota-regulated mechanism.
As a member of the PKC family of proteins, PKCiota has emerged as an oncogene in several tumor types including, ovarian, glioblastoma, lung cancer and pancreatic cancers. 10, 11, 20, 21 Several oncogenes have demonstrated a capacity to activate PKCiota, including KRAS, PI3K, Brc-Abl, Src, epidermal growth factor receptor and HER2/neu. 22 Both cyclin E and PKCiota individually have been implicated in anchorage-independent growth and transformation, one of the initial events in ovarian tumorigenesis. [23] [24] [25] [26] Thus, we hypothesized that with PKCiota and cyclin E having seemingly overlapping roles during tumor transformation requiring PKCiota overexpressing cells to maintain cyclin E expression during transformation. The downstream activation of cyclin E via PKCiota suggests that deregulation of the cell cycle lies at a central node of several oncogenic signaling pathways, which may be a crucial checkpoint of ovarian tumorigensis. Loss of PKCiota correlates with loss of cyclin E expression both in vivo and in vitro, leading to inhibition of tumor growth, aberrant acini formation, activation of subsequent PI3K feedback loop and prolonged overall survival of xenografted mice. The ability to attenuate the PKCiota → cyclin E pathway via PI3K inhibitors demonstrates a possible therapeutic target for PKCiota/ cyclin E-overexpressing ovarian tumors.
Cyclin E and the LMW-E isoforms have a potent role during oncogenic transformation of breast tissue. 27, 28 Research in our lab has also determined that LMW-E is a viable target in breast cancer, specifically in the triple-negative subset of breast cancer. 28 Owing to lack of estrogen receptor, progesterone receptor and HER-2, which provide functional targets for treatment, triple-negative breast cancer tends to be more aggressive and more difficult to treat. PKCiota, which is an oncogene, is also overexpressed in breast cancer 29, 30 and, recently, several publications have emerged that establish PKCiota as an essential driving force in triple-negative breast cancer. 31, 32 These studies suggest that PKCiota mediates its oncogenic activity in breast cancer through suppression of senescence and colocalization with MT1-MMP, which is responsible for invasion through degradation of the extracellular matrix. Because of the ability of oncogenic LMW-E to bypass normal cell cycle checkpoints [33] [34] [35] [36] and upregulation of LMW-E in invasive tumors (this study and Bales et al. 37 ), we reason that the oncogenic role of PKCiota in triple-negative breast cancer could at least in part be carried.
In ovarian cancer however, we show that neither EL nor the LMW-E isoforms demonstrated any regulatory capacity over PKCiota protein expression or phosphorylation. In addition, induced expression of EL and LMW-E isoforms abolished the inhibition of colony formations observed in PKCiota shRNA knockdown cells. This data strengthens the model of downstream activation of cyclin E by PKCiota; however, it also signifies the influential role cyclin E has in ovarian tumorigenesis. We have also observed a proteosomal-dependent degradation mechanism of cyclin E/LMW-E regulation by PKCiota. The specific mediators of this aspect of the pathway remain unknown.
Our efforts to elucidate this novel PI3K, PKCiota and cyclin E pathway provide a novel target for therapeutic intervention for ovarian tumors. As stated previously, phospho-PKCiota and cyclin E are possible biomarkers that could be used to evaluate PI3K Figure 6 . PKCiota regulates cyclin E through its degradation rather than transcription. IGROV cells were transfected with siControl or siPKCiota and subjected to (a) western blot analysis with the indicated antibodies and (b and c) quantitative reverse transcriptase-PCR (qRT-PCR). To this end, on transient knockdown of PKCiota for 24, 48, 72 and 96 h, RNA was collected at each time point and used for measurement of (b) cyclin E and PKCiota levels or (c) total FBW-7 levels. IGROV cells infected with cyclin E-T1 (IGROV-T1) was used as control for cyclin E primers. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control in the qRT-PCR assay, and the results for cyclin E and PKCiota for each condition was normalized with GAPDH. Experiment was repeated three times. (d) IGROV-stable shPKCiota cells and 293Ttransient siPKCiota cells were treated with MG132, and western blot analysis was performed using phospho-PKCiota, PKCiota, cyclin E, p21 (control for MG132 response) and actin (loading control). Although all samples were run on the same gel, the exposure time for cyclin E and p21 western blottings were much longer in the 293T cells than the IGROV cells, owing to the low endogenous levels of these two proteins in 293T cells. (e) Cyclin E and PKCiota levels were quantitated by densitometric analysis for (d) 293T and IGROV cells. 38, 39 providing additional rational for investigation of CDK inhibitors in this subset of PKCiota-driven ovarian tumors. Most notably, there are no specific PKCiota inhibitors presently available for clinical evaluation, thus providing rationale for the investigation of small-molecule inhibitors that target either PKCiota activity or phosphorylation. Lastly, in serous epithelial ovarian cancer, as PKCiota is consistently mislocalized or overexpressed at least in part owing to amplification of PKCiota and potentially PIK3CA, the gene that encodes the catalytic subunit of PI3K at 3q26.2, 13 ovarian cancer patients with this cancer subtype would be most likely to benefit from PKCiota inhibition.
MATERIALS AND METHODS
Detailed description of methods on tissue culture conditions, growth curve analysis, flow cytometry analysis, cell sorting using GFP, apoptosis assays, 3D culture conditions and assay, soft agar colony formation, confocal microscopy, western blot analysis, MG132 treatment, luciferase assay and immunohistochemical analysis of tumor tissues is provided in the Supplementary Methods.
Generation of PKCiota constructs pCMV6-XL5 PKCiota WT cDNA was purchased from Origene (Rockville, MD, USA; SC118455) and mutated by site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis kit (Agilent, Santa Clara, CA, USA). The CA mutation (A129E) and the DN mutation (K122STOP) were performed using primer described and validated previously. 40, 41 Confirmation of the targeted mutation was through sequencing using the T7 primer for transfection into 293T cells.
Infection with Ad-cyclin E/ Ad-E2F1
Cyclin E (EL, LMW-E-T1 and LMW-E-T2), E2F1 and LacZ adenoviruses were constructed using the AdEasy XL adenoviral vector system kit (Agilent). IGROV cells (1 × 10 6 cells/10 cm plate) were infected with 1000 multiplicity of infection of either Ad-Cyclin EL, Ad-LMW-E-T1 or Ad-LMW-E-T2 as published. 34, 42 Cells were then collected and examined by western blot analysis with indicated antibodies. Transfections siRNA to PKCiota in OVCAR3, IGROV and SKOV3 was performed using siPORT amine reagent (Ambion, Grand Island, NY, USA) using the reversetransfection protocol according to the manufacturer's instructions. Cells (2.3 × 10 5 ) were used per well of six-well plates. PKCiota siRNA (20 nM; gene code 309 and 311) and Silencer Negative Control Number 1 (catalogue number 4611), both from Ambion, were transfected with X-tremeGENE (Genentech, San Francisco, CA, USA), according to the manufacturer's protocol. To select stable IGROV cells, they were transfected with pRS-shPKCiota (Origene, #TR320472) using GeneJuice (Millipore, Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's protocol. shPKCiota 7 sequence 5′-TGACCAGAACACAGAGGATTATCTCTT CC-3′ targeting exon 14 and and shPKCiota 8 sequence 5′-CAGGA GATACAACCAGCACTTTCTGTGGT-3′ targeting exon 13 were determined to target only a single sequence. shControl (shRNA 3; 5′-CCTAAGGTTAAG TCGCCCTC-GCTCGAGCGAGGGCGACTTAACCTTAGG-3′) was the control, not specific for PKCiota. Stable clones were selected using 1 μg/ml Puromycin. OVCA420 cells were transfected with pcDNA3.1 constructs containing sequences coding for full-length cyclin E (EL) or the LMW-E forms (T1 and T2) using fuGENE 6 (Roche, Roche Diagnostics) according to the manufacturer's instructions.
Xenograft studies
Cells (1x10 6 ) were injected into the mammary fat pad of 4-to 6-week-old female Balb/c Nu/nu mice (Taconic, Germantown, NY, USA). To observe effects of PKCiota knockdown on tumor growth, 30 nude mice were randomized into two groups and injected with shControl (n = 15) or shPKCiota (n = 15) cloned cells in the mammary fat pads. The tumor volume was calculated every other day. Mice were euthanized when tumors were > 1.5 cm in diameter at the widest dimension of the tumor. Mice were housed five per cage in sterilized micro-isolator cages (Lab Products, Seaford, DE, USA) furnished with corncob bedding. The investigator who injected the mice with the shControl and shPKCiota cells was blinded to this groupings. Once the tumor measurement and survival data were captured, the identity of mice were revealed. Mice received care in accordance with the Animal Welfare Act, the National Institutes of Health 'Guide for the Care and Use of Laboratory Animals' and the institutional guidelines of MD Anderson Cancer Center.
RPPA analysis
RPPA, a high-throughput technique of quantitated proteomic analysis, was performed as previously published. 43 293T cells were transfected with either vector alone, PKCiota WT, CA or DN and collected 48 h later. Lysates were printed onto nitrocellulose-coated glass slides using an automated robotic arrayer (GeneTac, BST Scientific, Buona Vista, Singapore). Primary antibody treatment was followed by washes and a biotinylated secondary antibody incubation. The amplified signal was detected by a readout device and quantitated using an automated RPPA module (MicroVigene-VigeneTech, Carlisle, MA, USA). Analysis of the quantitated RPPA data was performed using Microsoft Excel.
PI3K inhibition
293T and IGROV cells were plated at 5 × 10 5 cells per 10-cm plate and were treated with PI3K inhibitors GDC-0941 and PI-103 (Selleck Chemicals, Houston, TX, USA) 24 h post plating. Following 24 h of treatment, cells were collected as above and subjected to western blot analysis.
Statistical consideration
All experiments were performed at least in triplicate. The results of each experiment are reported as the mean of experimental replicates. Error bars represent the s.d. from the mean. If not otherwise indicated, pairwise comparisons were analyzed using the unpaired two-sided t-test (GraphPad Prism, Buona Vista, Singapore). For all tests, Po0.05 was considered significant.
Linear regression curves were plotted on Microsoft Excel using the x-y scatter graph function. A linear trendline was established for each and the correlation coefficient was determined by Pearson test for the correlation coefficient (r). The P-value was determined using a significance calculator examining the r-value and the number of trials. The Student's t-test (twotailed, equal variance) was employed to derive the P-value of the experiments with a normal distribution.
